

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

74

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification:

C07D 257/02, 401/12
A61K 39/44, 49/00

A1

(11) International Publication Number:

WO 89/01476

(43) International Publication Date: 23 February 1989 (23.02.89)

(21) International Application Number: PCT/GB88/00671

(22) International Filing Date: 12 August 1988 (12.08.88)

(31) Priority Application Number: 8719042

(32) Priority Date: 12 August 1987 (12.08.87)

(33) Priority Country: GB

(71) Applicant (for all designated States except US): CELL-TECH LIMITED [GB/GB]; 216 Bath Road, Slough, Berkshire SL1 4EN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): PARKER, David [GB/GB]; 12 East Atherton Street, Durham DH1 4DG (GB). MILLICAN, Thomas, Andrew [GB/GB]; 3 Harcourt Close, Dorney Reach, Maidenhead, Berkshire SL6 0DY (GB).


(74) Agent: HALLLYBONE, Huw, George; Carpmaels and Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).

(81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent), US.

Published

With international search report.

(54) Title: TETRA-AZA MACROCYCLES AND METAL COMPLEXES THEREOF



(I)

(57) Abstract

Tetra-aza macrocycles of formula (I), wherein m and n, which may be the same or different, is each zero or an integer 1, 2, or 3; d is zero or an integer 1 or 2; q is zero or an integer from 1 to 6 inclusive; R¹, R² and R³, which may be the same or different, is each a hydrogen atom or an alkyl, alkoxyalkyl, -CO₂H, -SO₃H, PO₃H₂ or aryl group; L is a covalent bond or linker group; Z is a hydrogen atom or a reactive functional group, with the proviso that when L is a covalent bond Z is a reactive functional group; and metal complexes and/or salts thereof; are described together with processes for their preparation and compositions containing them. The compounds are useful for imaging and in the treatment of abnormal cell disorders, such as in the treatment of tumours, and are particularly suitable for coupling to other molecules, such as proteins for use in diagnosis and therapy.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

TETRA-AZA MACROCYCLES AND METAL COMPLEXES THEREOFField of the Invention

5

This invention relates to functionalised tetra-aza macrocycles, to metal complexes thereof, to conjugate compounds containing the functionalised tetra-aza macrocycles and metal complexes thereof and to their use in diagnosis and therapy.

10

Background to the Invention

15

The attachment of metal ions to proteins, peptides and other, smaller molecules is a fast expanding technology, which has numerous proven and potential applications in research, in industry and, particularly, in medicine.

20

In recent years, much of the impetus behind the development of this technology has been the ability to link metal ions to antibodies, especially monoclonal antibodies. Such metal labelled antibodies have found a widespread use, especially in medicine, where they have been employed, for example, to target the metal ion to a specific tissue type, both in vitro and in vivo. Thus, metal labelled antibodies have applications in locating specific tissue types (e.g. employing computer-aided tomographic techniques where the metal ion is in some way detectable) and in the treatment of cell disorders (e.g. treating mammalian tumours where the metal ion is a cytotoxic radionuclide).

25

30

Conventionally, attachment of the metal ion to a protein such as an antibody has been achieved by complexation by an acyclic chelate such as a substituted diethylenetriaminepentaacetic acid [Gansow O. A. et al, Inorg. Chem., (1986), 25, 2772] or ethylenediaminetetraacetic acid [Meares, C. F. et al, Acc. Chem. Res., (1984), 17, 202] covalently linked to the antibody. Such acyclic complexes however tend to be unstable in vivo either as a

35

-2-

5 result of acid-catalysed decomplexation or competitive chelat binding by Ca^{2+} or Zn^{2+} in serum, or as a result of competition from transferrin [Moerlein, S. M. et al, Int. J. Nuc. Med. Biol., (1981) 8, 277]. The lack of stability can result in uncomplexed metal atoms in the body which have a cytotoxic effect on healthy tissue (e.g. bone marrow) or which markedly reduce the signal-to-noise ratio of an imaging technique.


10 A possible alternative to the use of acyclic chelates in the labelling of antibodies is the use of macrocyclic ligands, which has been suggested in broad terms [Gansow O.A. et al. Am. Chem. Soc. Symp. Ser., (1984), 241, 215; UK Patent Specification Publication No. 2122641; and Moi M. K. et al, Anal. Biochem., (1985), 148, 249-253].

15 We have now found a new class of functionalised tetra-aza macrocycles, members of which are able to form more kinetically inert complexes with metal ions than are chelating agents conventionally in use for the attachment of metal ions to proteins and other
20 molecules. The macrocycles of the invention are particularly useful for attachment to proteins, especially antibodies, to provide conjugate compounds capable of binding metals to give complexes which are advantageously stable in vivo.

-3-

Summary of the Invention

Thus, according to one aspect of the present invention we provide a compound of general formula (1):



wherein

m and n , which may be the same or different, is each zero or an integer 1, 2, or 3;

d is zero or an integer 1, 2 or 3;

q is zero or an integer from 1 to 6 inclusive;

R , R^1 , R^2 and R^3 , which may be the same or different, is each a hydrogen atom or an alkyl, alkoxyalkyl, $-\text{CO}_2\text{H}$, $-\text{SO}_3\text{H}$, $-\text{PO}_3\text{H}_2$ or aryl group;


L is a covalent bond or a linker group;

Z is a hydrogen atom or a reactive functional group, with the proviso that when L is a covalent bond Z is a reactive functional group;

and metal complexes and/or salts thereof.

In the compounds of formula (1), alkyl groups represented by R , R^1 , R^2 and R^3 may be for example C_{1-6} alkyl groups such as methyl or ethyl groups. Alkoxyalkyl groups represented by R , R^1 , R^2 or R^3 may be for example C_{1-3} alkoxy C_{1-3} alkyl groups e.g. methoxymethyl. When R , R^1 , R^2 or R^3 is an aryl group it may be for example a substituted phenyl group, such as a group of formula (where R^4 is a hydrogen atom or a C_{1-6} alkyl, e.g. methyl, C_{1-3} alkoxy C_{1-3} alkyl, e.g. methoxymethyl, or C_{6-12} aryl, e.g. phenyl group).

-4-

In general, compounds of formula (1) in which R, R¹, R² and R³ are the same are preferred. Compounds of this type in which q is an integer from 1 to 6 inclusive, particularly an integer 1, and R¹, R² and R³ are -SO₃H, -PO₃H₂  or, in particular, -CO₂H, are especially preferred.

5

In the compounds of formula (1), it will be appreciated that the nature of the group L when it is a linker group may be varied widely without substantially affecting the usefulness of compounds of formula (1) and the metal complexes thereof. Thus L may be any suitable organic radical and may be for example an optionally substituted aliphatic hydrocarbyl chain, optionally interrupted by one or more heteroatoms selected from -O- or -S- or by one or more -N(R⁵)- (where R⁵ is a hydrogen atom or a C₁₋₆ alkyl group), -CON(R⁵)-, -N(R⁵)CO-, cycloaliphatic, aromatic, or heteroaromatic groups.

15

In the above definition, and in the same context whenever it appears below, the term "interrupted by" as applied to cycloaliphatic or aromatic groups is to be understood to also mean that these particular groups may additionally be present linked to the terminal carbon atom of the hydrocarbyl chain represented by L, at the opposite end of the chain to the carbon atom attached to the macrocycle.

20

25

Thus, for example, L may be an optionally substituted straight or branched C₁₋₂₀ alkylene, C₂₋₂₀ alkenylene, or C₂₋₂₀ alkynylene chain, optionally interrupted by one or more -O- or -S- atoms or C₅₋₈ cycloalkylene (e.g. cyclopentylene or cyclohexylene), C₆₋₁₂ aromatic (e.g. phenylene or substituted phenylene), C₅₋₁₀ heteroaromatic (e.g. furanyl, pyridyl), -N(R⁵)-, -CON(R⁵)- or -N(R⁵)CO- groups.




30

-5-

Examples of substituents which may be present on the chain L include halogen atoms, e.g. fluorine, chlorine, bromine, or iodine atoms or groups selected from C_{1-6} alkoxy (e.g. methoxy or ethoxy), hydroxy, nitro, $-N(R^6)(R^7)$, [where R^6 is a hydrogen atom or a C_{1-6} alkyl group and R^7 is a C_{1-6} alkyl group; e.g. $-NHCH_3$ or $-N(CH_3)_2$], or substituted amido, e.g. a group of formula $-(CH_2)_n CON(R^8)(R^9)$ [where n is zero or an integer 1 to 4 inclusive, R^8 is a hydrogen atom or a C_{1-6} alkyl group, e.g. methyl and R^9 is an optionally substituted C_{1-6} alkyl group].

Substituted alkyl groups represented by R^9 include for example C_{1-6} alkyl groups substituted by one or more halogen atoms, or nitro, amino or hydroxy groups.

In general, in compounds of formula (1) the linker group is preferably an optionally substituted C_{1-10} alkylene, (especially C_{1-6} alkylene such as methylene, ethylene, propylene, butylene, pentylene or hexylene) C_{2-10} alkenylene or C_{2-10} alkynylene chain optionally interrupted by one or more -O- or -S- atoms or cyclohexylene, phenylene, substituted phenylene, -NH-, $-N(CH_3)-$, -CONH-, $-CON(CH_3)-$, -NHCO- or $-N(CH_3)CO-$ groups.


Particular examples of linker groups represented by L include, for example, $-(CH_2)_d-$ (where d is an integer 1 to 4 inclusive), $-(CH_2)_d$ -, $-(CH_2)_d$ -- CH_2NHCO -- CH_2 , $-(CH_2)_dNHCO(CH_2)_e-$ (where e is an integer 1 to 4 inclusive) and $-(CH_2)_dNHCO(CH_2)_eOCH_2-$.

The reactive functional group represented by Z in compounds of formula (1) may be any group capable of reacting with a thiol, amino, carboxyl, hydroxyl, aldehyde, aromatic or heteroaromatic group. Aromatic groups include, for example, phenolic groups. Heteroaromatic groups include for example imidazolyl groups.


Thus, Z may be, for example, a halogen atom, for example a chlorine, bromine or iodine atom, or a group selected from -SH, -NH₂, hydrazine (-NHNH₂) or a derivative thereof, [for example -N(CH₃)NH₂, -NHCONHNH₂, -NHCSNHNH₂, or phenyl hydrazine], -NCO, -NCS, -COR¹⁰,

5 [where R¹⁰ is a halogen atom such as a chlorine or bromine atom, or a N₃, C₁₋₆alkoxy, e.g. methoxy, C₆₋₁₂aryloxy (e.g. nitrophenyloxy or dinitrophenyloxy), imidyloxy (e.g. succinimidyloxy) or imidazoloyloxy group], imide, e.g. maleimide, a vinyl group of formula
 10 -Het¹-C(Het²)=CH₂ (where Het¹ and Het², which may be the same or different, is each a nitrogen containing heterocyclic group, e.g. a pyridyl group or Het¹ is a nitrogen containing heterocyclic group and Het² is a hydrogen atom), for example a vinyl pyridyl group of formula

15




or




20

especially




or



25

or a dione of formula




-7-

(where R^{11} is a C_{1-4} alkyl e.g. methyl, group).


Metal complexes of the compounds of formula (1) include complexes wherein the metal is di- or tripositive and has a coordination number 6 or greater, especially 8. Examples of such metals include indium (In), copper (Cu), lead (Pb), bismuth (Bi), yttrium (Y), terbium (Tb), gadolinium (Gd) and Scandium (Sc). Y, Pb, Tb, Gd, and Sc are preferred, particularly Y, Gd and Pb. In general the metal is preferably a radioactive isotope. Yttrium, especially ^{90}Y , is particularly preferred.

In general, optimum binding of the metal to the compounds of formula (1) may be achieved by selection of the ring size and where appropriate by adjusting the potential coordination number by choice of the group $(CH_2)_q R$, $-(CH_2)_q R^1$, $-(CH_2)_q R^2$, and/or $-(CH_2)_q R^3$. Thus a particularly important class of compounds of formula (1) is that wherein d is an integer 1. Especially useful compounds are those wherein d is an integer 1, m is an integer 1 or 2 and n is an integer 1 or 2. In general, compounds of formula (1) in which $-(CH_2)_q R$, $-(CH_2)_q R^1$, $-(CH_2)_q R^2$ and $-(CH_2)_q R^3$ is each $-CH_2CO_2H$ are particularly useful.

Salts of the compounds of formula (1) include salts with bases, e.g. sodium or potassium salts, or acid addition salts such as hydrobromides or hydrochlorides. Pharmaceutically acceptable salts are particularly preferred.

A particularly useful group of compounds of the invention has the formula (1) wherein R, R^1 , R^2 , R^3 , m, n, d and q are as defined for formula (1) and the groups -L and Z together represent a group (1) $-(CH_2)_r -X-Y$ [where r is zero or an integer from 1 to 6 inclusive, X is a group -NH-,  $-(CH_2)_s NH-$ (where R^4 is a previously defined and s is zero or an integer 1 to 4 inclusive), $-(CH_2)_s NHNH-$ or $-(OCH_2CH_2)_t NH-$ (where t is an integer 1 to 6 inclusive) and Y is


-8-

a group $-\text{COZ}^1$ or $-\text{CO(R)Z}^1$ (where R is a spacer group, and Z^1 is a group $-(\text{CH}_2)_t\text{Hal}$ (where Hal is a halogen atom), , or $-\text{C(R}^{12})\text{CH}_2$ (where R^{12} is a nitrogen containing aromatic heterocyclic group, for example a pyridyl group)], or (2) a group $-(\text{CH}_2)_r\text{NCS}$; and the metal complexes and/or salts thereof.

In compounds of this type, the spacer group R may be for example an alkylene, e.g. ethylene, alkoxyalkylene, e.g. methoxymethylene, aryl, e.g. phenylene, aralkylene, e.g. phenalkylene such as phenethylene, or cycloalkylalkylene, e.g. cyclohexylmethylene group.

A further particularly useful group of compounds according to the invention has the formula (1) wherein R , R^1 , R^2 , R^3 , m, n, d and q are as defined for formula (1) and the groups L and Z together represent a group $-(\text{CH}_2)_r\text{XH}$ (where r and X are as defined above) and the metal complexes and/or salts thereof.

An important group of compounds according to the invention has the formula (1a):



(1a)

wherein R , R^1 , R^2 , R^3 , L and Z are as defined for formula (1) and metal complexes and/or salts thereof.

Compounds of this type in which R , R^1 , R^2 and R^3 is each $-\text{CO}_2\text{H}$ are particularly preferred.

-9-

Compounds of formula (1a) in which L is a linker group [particularly those specifically identified for compounds of formula (1)] are especially useful.

5 Z in compounds of formula (1a) is preferably a reactive functional group, [particularly those specifically identified for compounds of formula (1)], especially a group of formula $\text{-Het}^1\text{-C(Het}^2\text{)=CH}_2$ or a dione of formula



10 Yttrium complexes of the compounds of formula (1a) are particularly useful.

15 The compounds of formula (1) and the metal complexes and/or salts thereof have a diagnostic use as imaging agents in vitro and in vivo. The compounds of formula (1) and the metal complexes and/or salts thereof are also cytotoxic agents and may be used in the treatment of abnormal cell disorders, for example in the treatment of tumours.

20 For application of the compounds of formula (1) as imaging or cytotoxic agents, it is generally preferable to couple the compounds to other molecules such as proteins, especially antibodies, peptid s or carbohydrates to form conjugate compounds, and the compounds of formula (1) are particularly well adapted for use in this respect.

25 Thus, according to a further aspect of the invention, we provide a conjugate compound which comprises a compound of formula (1), or a metal complex and/or salt thereof, coupled to a protein, peptide or carbohydrate.


30 The compound of formula (1) may be coupled through any thiol, amino, carboxyl, hydroxyl, aldehyde, aromatic or heteroaromatic group present in the protein, peptide or carbohydrate.

-10-

In a preferred aspect of the invention, we provide a conjugate compound which comprises a compound of formula (1) or a metal complex and/or salt thereof, coupled to an antibody.

5 It is to be understood that conjugate compound according to the invention may contain more than one molecule of a compound of formula (1) coupled to any one protein, peptide or carbohydrate molecule.

10 In a particular aspect, the invention provides a conjugate compound of formula



20 wherein m, n, d, q, R, R¹, R², R³, and L are as defined for formula (1);



Z¹ is the residue of a reactive functional group;

w is zero or an integer 1;

25 z is an integer 1 or more;

Ab is an antibody; and metal complexes and/or salts thereof.

30 In the compounds of formula (2), the residue of a reactive functional group represented by Z¹ may in general be the residue of a reactive functional group Z as defined for formula (1).

In particular, Z¹ may be for example -S-, -NH-, -NHN=, -N(CH₃)N=, -NHCONHN=, -NHCSNHN=, -N(Ph)N= (where Ph is phenyl, -NC(O)-, -NC(S)-, -CO-, , -H t¹ -C(Het²)CH₂- r 

-11-

The antibody Ab in the conjugates of formula (2) may be a complete antibody molecule or a fragment thereof, or an analogue or either of these, provided that the antibody comprises of a specific binding region. Thus the antibody may be polyclonal, or, preferably, monoclonal, or a fragment thereof for example a Fab' or F(ab)₂' fragment. If desired the antibody may be a recombinant antibody, (i.e. an antibody which has been produced using recombinant DNA techniques). The antibody may be a chimaeric antibody comprising linked antibody fragments, each from a different source (see for example International Patent Specification No. WO 86/01533).

The antibody may be specific for any number of antigenic determinants, but is preferably specific for one antigenic determinant. Particular determinants include tumour cell-associated antigens, particularly mammalian tumour cell antigens for example oncofetal antigens such as carcinoembryonic antigen or alphafetoprotein.

A particular useful antibody is that known as B72.3 [Colcher, D. et al Proc. Nat. Acad. Sci. USA (1981), 78, 3199].

The antibody Ab will in general be coupled to the remainder of the conjugate of formula (2) (i.e. the macrocycle and linker) through any appropriate reactive atom or group, for example a nitrogen or, especially, sulphur atom, present in the antibody. It will be appreciated that any one antibody molecule may contain more than one reactive group capable of coupling with the macrocycle and linker. Thus, for example, z in the conjugates of formula (2) may be an integer 1, 2, 3, 4, 5, 6 or more depending on the number of macrocycles linked to any particular antibody molecule or fragment or analogue thereof.

Yttrium complexes of conjugates of formula (2) are particularly useful.

-12-

It is to be understood that the definitions and preferences expressed for m, n, d, q, R, R¹, R², R³ and L in compounds of formula (1), and for classes of compounds of formula (1) are also applicable to conjugates of formula (2).

5

Particularly useful conjugate compounds according to the invention are those comprising a compound of formula (1a), or a metal complex and/or salt thereof, coupled to an antibody. The indium complexes of these conjugates are especially important.

10

The compounds of formulae (1) and (2) may be formulated for use in accordance with conventional practice, and thus according to a further aspect of the invention we provide a composition comprising a compound of formula (1) or a compound of formula (2) or a metal complex and/or salt thereof, together with one or more pharmaceutically acceptable carriers.

15

20

Particularly suitable compositions according to the invention are those adapted for parenteral administration, especially intravenous administration. Suitable formulations of this type include solutions of the compounds of formulae (1) or (2) in isotonic saline.

25

The quantities of compounds of formulae (1) or (2) used in formulations according to the invention will vary according to the intended use (i.e. imaging or therapy) and other variables such as the intended cell target, but may be easily determined in accordance with conventional practice for reagents of this type.


30

Compounds of the invention may be prepared by the following processes wherein the groups and symbols R, R¹, R², R³, m, n, d, q, L, Z, Ab and z are as defined for formulae (1) and (2) except where stated otherwise. Where a metal complex is desired as a final product, the complexation with a metal atom may be carried out as a

-13-

final step in the production process, as described below for the complexation of compounds of formulae (1), or alternatively it may be desirable to complex the metal at an earlier stage in the process, providing of course that the requisite macrocycle structure is present. In the following processes, it may be desirable to use starting materials in which the group Z is in a protected state, or which contain a precursor of the group, as discussed below.

Thus, according to a further aspect of the invention a compound of formula (1) or a metal complex thereof may be prepared by reaction of a corresponding compound of formula (3)



or a metal complex thereof, with a reagent $R^1(CH_2)_q D$ (where D is a displaceable group). Displaceable groups represented by D include for example halogen atoms, for example a bromine, chlorine or iodine atom.

The reaction may be performed in a solvent such as water or an organic solvent such as a nitrile e.g. acetonitrile or an alcohol e.g. isopropanol or an amide e.g. dimethylformamide in the presence of a base, e.g. an inorganic base such as an alkali metal carbonate or hydroxide, e.g. sodium, potassium or caesium carbonate, or sodium, potassium or lithium hydroxide, at a high temperature e.g. the reflux temperature.

In this reaction, the group Z may need to be in a protected state. Conventional protecting groups may be used, depending on the nature of Z, and may be removed using standard procedures, once the desired

-14-

reaction has been effected. Similarly, when the reagent $R^1(CH_2)_qD$ contains an acid group this may also need to be protected, for example as an ester e.g. a methyl ester. The acid may be re-generated after the desired reaction is complete, for example by hydrolysis using an acid such as sulphuric acid.

5

It will be appreciated that where it is desired to prepare a compound of formula (1) in which R , R^1 , R^2 and R^3 are not the same this may be achieved by first selectively N-protecting the compound of formula (3) or a precursor using an appropriate amine protecting group(s), for example a p-toluenesulphonyl group as described below, in accordance with conventional practice. Reaction of the N-protected compound (3) with $R^1(CH_2)_qD$ followed by deprotection and further reaction as necessary with other reagents $R^1(CH_2)_qD$ then yields the desired compound in which R , R^1 , R^2 and R^3 are not the same.

10

15

Where metal complexes of compounds of formulae (1) or (2) are required (or any other suitable macrocyclic intermediate described herein) these may be prepared by treating the compound with a metal salt (for example a metal halide) in an appropriate solvent for example an aqueous or non aqueous solvent, (e.g. acetonitrile, acetone, propylene carbonate, dimethylformamide or dimethylsulphoxide) at any suitable temperature from 0°C to 100°C such as 10° to 80°C e.g. around 60°C .

20

25

In another process, a compound of formula (1) or a metal complex thereof wherein R , R^1 , R^2 and R^3 is each $-(CH_2)_qPO_3H_2$ (where q is an integer 1 to 6) may be prepared by reaction of a compound of formula (3) or a metal complex thereof with phosphorous acid and an aldehyde R^bCHO (where R^b is a hydrogen atom or a C_{1-5} alkyl group) in the presence of an acid, such as hydrochloric acid at an elevated temperature, e.g. $100^\circ-130^\circ\text{C}$.

30

-15-

Compounds of formula (1) may also be prepared by interconversion from other compounds of formula (1). Thus one functional group Z may be exchanged for another and, if desired a linker group L changed to another by appropriate manipulative reactions. For example, a compound of formula (1) where $-L-Z$ is a group $-L^1-NHCO-L^2-Z$ (where $-L^1-NHCO-L^2$ represents the group L) may be prepared by reaction of a corresponding compound wherein $-L-Z$ represents $-L^1-NH_2$ with a reagent R^bO-L^2-Z (where R^b is for example an imide, such as succinimide, or a substituted phenyl group such as a p-nitrophenyl group) in the presence of a tertiary amine, such as diisopropylethylamine, in a solvent such as dimethylformamide.

Reagents of formula R^bO-L^2-Z are either known compounds or may be obtained from known starting materials using methods analogous to those used for the preparation of the known compounds.

A conjugate compound of formula (2) or a metal complex thereof may be prepared by reaction of a corresponding compound of formula (1) or a metal complex thereof with an antibody Ab (as previously defined).


The reaction may be performed in a suitable solvent, for example an aqueous solvent such as a phosphate buffer, at an appropriate temperature, for example at $0^\circ-30^\circ\text{C}$, especially $0^\circ-10^\circ\text{C}$ e.g. 4°C .

The antibody Ab may be obtained using procedures well known in the art. If desired, before the coupling reaction, the antibody may first be treated to yield appropriate groups for reaction with the compound of formula (1). Thus for example the antibody may be subjected to oxidation, for example periodate oxidation to yield aldehyde groups, or, in particular, may be treated with a reagent [e.g. Traut's reagent (2-iminothiolane)] using standard procedures to generate free sulphydryl groups in the molecule.

-16-

Salts of compounds of formulae (1) or (2) and their metal complexes may be prepared by conventional means, for example by reaction with an appropriate base or acid in a suitable aqueous solvent.

5 Intermediates of formula (3) may be prepared by deprotection of a compound of formula (4)



15 (where R^{13} is a protecting group such as a p-toluenesulphonyl group. The deprotection will depend on the nature of the protecting group R^{13} . Thus, for example, when R^{13} is a p-toluenesulphonyl group removal of this may be achieved by treatment of the compound

20 of formula (4) with an acid, for example HBr-acetic acid, in the presence of phenol at a high temperature, or by reaction with lithium in liquid ammonia in the presence of an alcohol such as ethanol.


25 Intermediates of formula (4) may be prepared by treating a compound of formula (5)



30 with a compound $R^{13}OCH_2(CH_2)_dOR^{13}$ in the presence of a base such as sodium ethoxide in a solvent such as dimethylformamide.

Intermediates of formula (5) may be prepared by reaction of compounds of formula (6)

-17-



with a protecting agent, for example p-toluenesulphonyl chloride in a base such as pyridine.

5

Intermediates of formula (6) in which m and n are the same may be prepared by reaction of a diamine of formula (7):



10

with a reagent $R^{13}NH(CH_2)_mCOHal$ (where Hal is a halogen atom) in the presence of a base such as triethylamine, followed by reduction using for example borane in a solvent such as tetrahydrofuran at a high temperature e.g. the reflux temperature, followed by treatment with an acid such as hydrochloric acid.


15

Where it is desired to prepare an intermediate of formula (9) in which m and n are not the same a protected amine $H_2NCH(L-Z)CH_2NHR^{13}$ may be used in the above reaction. Removal of the protecting group after the reaction followed by repeated alkylation with a different compound $R^{13}NH(CH_2)_nCOHal$ then yields the required intermediate.

20

Diamines of formula (7) may be prepared from an appropriately substituted amino acid of formula (8):

25




by reaction with ammonia in a solvent such as methanol, followed by reduction using for example lithium aluminium hydride.

30

The substituted amino acids of formula (8) are either known compounds or may be prepared using methods analogous to those used for the preparation of the known compounds.

-18-


In an alternative process, intermediates of formula (5) may be prepared by reaction of a compound of formula (9)



5

with a compound $R^{13}OCH_2(CH_2)_dN(R^{13})(CH_2)_mCH_2OR^{13}$ in the presence of a base such as caesium carbonate in a solvent such as dimethylformamide.

10 Intermediates of formula (9) may be prepared by reduction of compounds of formula (10)



15 using for example borane as described above, followed by reaction to introduce the protecting group R^{13} , for example with p-toluenesulphonyl chloride in a solvent such as dichloromethane in the presence of a base such as triethylamine at e.g. reflux.

20 Intermediates of formula (10) may be prepared by reaction of an appropriately substituted amino acid of formula (8)

(where R^{11} is a methyl or ethyl group) with a diamine



25

The invention is illustrated by the following Examples.

-19-

Description of Specific EmbodimentsIntermediate 1

5

2,6-Diamino-1-hexanoic acid, ethylenediamine ester

10

15

2,6-Diamino-1-hexanoic acid, methyl ester, dihydrochloride (10.283g) was added (as solid) in small batches over a 50 minute period to ethylenediamine (100ml) at 90°C, with stirring. The temperature of the reaction mixture was then raised to 140°C for 6hrs, after which the ethylenediamine was removed by vacuum distillation to yield a brown residual oil which was taken up in 4M NaOH (25ml) and dried in vacuo. Methanol (30ml) was added, the solution was filtered, the methanol removed (Buchi) and the residue dissolved in CH₂Cl₂ (100ml), then filtered, and the filtrate rotovated down to give the title compound as a clear brown oil (8.827g). i.r (thin film) 3300/3280 3060 2930 2860 1650 1570 1470 1320cm⁻¹.

20

Intermediate 21,5,9-Triamino-3-aza-nonane, tetrahydrochloride

25

30

Intermediate 1 (3.754g) and borane-tetrahydrofuran (130mmol, 130ml) was refluxed for 21 hours. After removal of volatiles, the aminoborane was washed with methanol (2 x 100ml) and hydrolysed with 6M HCl (150ml, 110°C) for 3 hours. The resulting solution was evaporated, methanol (20ml) added and further evaporated to yield the title compound (6.279g) as a white hygroscopic solid.

-20-

Intermediate 31,5-Diamino-(9-N-benzamidy)1-3-aza-nonane

5 Intermediate 2 (6.16g) and potassium hydroxide (4.4g) was dissolved
in water (50ml) and, with stirring, copper carbonate (2.603g) was
added. Continued stirring over 30 minutes at 50°C yielded an
intense blue solution which was cooled to 0°C and benzoyl chloride
2.5ml added in 0.25ml portions over 90 minutes keeping the pH
10 greater than 9 with periodic addition of KOH pellets. The solution
was then allowed to stir at room temperature for 1 hour, then
filtered and the filtrate treated with H₂S over 30 minutes. The
solution was filtered once again to give a greeny-yellow filtrate
which on addition of KOH to pH14 went a dark green, with a small
15 amount of green precipitate. This was filtered off, the filtrate
reduced in volume to 40ml and exhaustively extracted (13x) with
CH₂Cl₂, dried (K₂CO₃), and evaporated to yield the title compound as
a pale yellow oil (2.152g). ¹H-NMR (250MHz), δ(CDCl₃): 1.57 (m,
16H, CH₂, NH, NH₂) 2.37 (dd, 1H, CH), 2.67 (m 3H, CH₂N), 2.79(m, 3H,
20 CH₂N).

-21-

Intermediate 41,5-Ditosylamino-3-tosyl-(9-N-benzamidyl)-3-aza-nonane

5 Intermediate 3 (1.978g) in dry CH_2Cl_2 (50ml) was added dropwise to a solution of tosyl chloride (5.087g), in dry CH_2Cl_2 (50ml) and the mixture was then allowed to stir for 2 1/2 hours at room temperature. The solution was then washed with water (20ml) dried (K_2CO_3), filtered and evaporated to an oily brown residue which was
10 redissolved in CH_2Cl_2 (10ml). After a few minutes a white solid precipitated which was collected by filtration and washed with CH_2Cl_2 to give the title compound (1.701g).
TLC (silica; 5% methanol in CH_2Cl_2) Rf 0.44 m/e [desorption chemical ionisation (methanol)] 741 ($\text{M}^+ + 1$), 740 (M^+).

15

Intermediate 5

20 2-(4-N-Benzamidyl)butyl-N.N'.N''.N'''-tetratosyl-1,4,7,10-tetrazacyclododecane.

Intermediate 4 (1.116g) was dissolved in anhydrous dimethylformamide (100ml) and caesium carbonate (1.032g) added under dry nitrogen. A solution of $\text{TsO}(\text{CH}_2)_2\text{N}(\text{Ts})(\text{CH}_2)_2\text{OTs}$ (0.855g; where Ts represents tosyl), in anhydrous dimethylformamide (40ml) was slowly added, with
25 stirring, over 3 hours. Stirring was continued at room temperature for 20 hours. The dimethylformamide was removed under reduced pressure and the residue dissolved in chloroform (200ml), washed with water (3 x 30ml) and dried (K_2CO_3) to yield the title compound. m/e [desorption chemical ionisation (iso-but)]:
30 964 ($\text{M}^+ + 1$), 963 (M^+).

-22-

Intermediate 62-(4-N-Benzamidyl)butyl-1,4,7,10-tetrazacyclododecane

5 To Intermediate 5 (0.499g) in a flask under nitrogen was added ethanol (2ml), and liquid ammonia (100ml) then allowed to condense in the flask. Lithium metal (0.18g) was added and an intense blue colour developed which discharged within 20 minutes. After evaporation of NH_3 (3 hours) water (20ml) was added and the solution
10 evaporated to dryness, taken up in 6 M HCl (20ml) washed with ether (3 x 20ml), evaporated to dryness and redissolved in 6M KOH (20ml) and extracted with dichloromethane (5 x 20ml). The extract was dried (K_2CO_3) and evaporated to yield the title compound (0.115g).
15 m/e [desorption chemical ionisation (methanol)]: 348 ($\text{M}^+ + 1$)

Example 1

20 2-O-(6-ethenyl)-2-(pyridyl)methyl-N-[4-[2-perhydro-1,4,7,10-tetrazadecine-1,4,7,10-tetra(2-acetic acid)butyl]]ethanamide]

2-(4-N-Benzamidyl)butylperhydro-1,4,7,10-tetrazadecine-1,4,7,10-tetra(2-acetic acid)

25 (a) Intermediate 6 (75mg) was dissolved in dry dimethylformamide (3ml) and K_2CO_3 (146mg) added, followed by methylbromoacetate (160mg). The mixture was heated to 90°C for 6 hours under nitrogen, further K_2CO_3 (30mg) and methylbromoacetate (32.3mg)
30 were added and the heating continued at 90°C for a further 12 hours under nitrogen. The mixture was filtered and water (3ml) added followed by lithium hydroxide monohydrate (50mg). The reaction was monitored by reverse phase high performance liquid chromatography (RPHPLC-conditions given below) and two new
35 products were formed (T=10.7 and 11.5 minutes). More lithium hydroxide

-23-

mon hydrate (50mg) was added and the reaction went to completion, the predominant product by RPHPLC eluting at 10.7 minutes. The reaction mixture was concentrated in vacuo to give a brown oil which was purified on DEAE Sepharose using a gradient elution of 25mM ammonium acetate (pH=5.6)/10% CH₃CN up to 1.0M ammonium acetate (pH5.6)/10% CH₃CN. The appropriate fractions were pooled and concentrated in vacuo to give the title compound (47mg) of Part (a) as a white solid. m/e (Fab, glycerol) 580 (M+H⁺).

RPHPLC CONDITIONS:

Column : Sperisorb SODS2 (25cm x 0.4mm)
 Flow Rate : 1.4ml/minute
 Solvents : A = 0.1% trifluoroacetic acid/H₂O
 B = 0.1% trifluoroacetic acid/CH₃CN
 λ = 254nm

TIME (T:minutes)	%A	%B
0	95	5
20	5	95
20.1	95	5

(b) 2-(4-Amino)butylperhydro-1,4,7,10-tetrazadecine-1,4,7,10-tetra
(2-acetic acid)

The compound of Part (a) [37mg] was dissolved in 6M HCl (10ml) and heated to 140°C for 16 hours under nitrogen. The reaction mixture was concentrated in vacuo and coevaporated with dry dimethylformamide (3 x 10ml) to yield the title compound of Part (b) which was used in the following reaction without further purification.

-24-

(c) 2-O-(6-ethenyl)-2-(pyridyl)methyl-N-[4-(2-perhydro-1,4,7,10-tetrazadecine-1,4,7,10-tetra(2-acetic acid)butyl]ethanamide]

5 The amine prepared in Part (b) was dissolved in dry dimethylformamide (10ml) and diisopropylethylamine (10mg) was added followed by the p-nitrophenyl ester of 2-vinyl-6-methoxyacetic acid pyridine (24mg). The reaction was monitored using ion exchange chromatography (Ax100 - conditions given below) and a new product was observed at T=13.3 minutes. Extra addition of the nitrophenyl ester/diisopropylethylamine did not give any increase in product and the reaction mixture was ninhydrin negative. The mixture was then concentrated in vacuo and water added followed by CH₂Cl₂. The aqueous layer was extracted with CH₂Cl₂ (3 x 20ml) and concentrated in vacuo. The residue was chromatographed on DEAR Sepharose eluting with 25mM up to 500mM ammonium acetate/CH₃CN (9:1) pH5.6. The product fractions were pooled and concentrated in vacuo to give the title compound (20mg) as a white solid. m/e (FAB, glycerol) 651 (M⁺+1).

Ax100 (Synchropak - 25cm x 0.4mm) ion exchange chromatography:

A = H₂O; B = 1M ammonium acetate, pH5.6; C = CH₃CN

Flow Rate = 1.4ml/minute; λ=254nm.


	TIME (T; minutes)	%A	%B	%C
30	0	70	10	20
	20	10	80	20
	20.1	70	10	20

Title Compound elutes at 13.3 minutes.

-25-

CLAIMS

1. A compound of formula (1):



wherein

m and n, which may be the same or different, is each zero or an integer 1, 2, or 3;

d is zero or an integer 1, 2 or 3;

q is zero or an integer from 1 to 6 inclusive;


R, R¹, R² and R³, which may be the same or different, is each a hydrogen atom or an alkyl, alkoxyalkyl, -CO₂H, -SO₃H, -PO₃H₂ or aryl group;

L is a covalent bond or a linker group;

Z is a hydrogen atom or a reactive functional group, with the proviso that when L is a covalent bond Z is a reactive functional group;


and metal complexes and/or salts thereof.

2. A compound according to Claim 1 wherein q is an integer from 1 to 6 inclusive and R, R¹, R², and R³ is each a -CO₂H group.
3. A compound according to Claim 2 wherein q is an integer 1.

4. A compound according to any of the preceding claims wherein L is an optionally substituted aliphatic hydrocarbonyl chain, optionally interrupted by one or more heteroatoms selected from -O- or -S- or by one or more -N(R⁵)- (where R⁵ is a hydrogen atom or C₁₋₆ alkyl group), -CON(R⁵)-, -N(R⁵)CO-, cycloaliphatic, aromatic, or heteroaromatic groups.
5. A compound according to any of the preceding claims wherein Z is a group capable of reacting with a thiol, amino, carboxyl, hydroxyl, aldehyde, aromatic or heteroaromatic group.
6. A compound according to Claim 5 wherein Z is a halogen atom or a group selected from -SH, -NH₂, hydrazine or a derivative thereof, -NCO, -NCS, -COR¹⁰ (where R¹⁰ is a halogen atom or a N₃, C₁₋₆ alkoxy, C₆₋₁₂ aryloxy, imidyloxy or imidazolyloxy group), imide, -Het¹-C(Het²)=CH₂ (where Het¹ and Het² which may be the same or different, is each a nitrogen containing heterocyclic group, or Het¹ is a nitrogen containing heterocyclic group and Het² is a hydrogen atom) or a dione of formula  (where R¹¹ is a C₁₋₄ alkyl group).
7. A metal complex of a compound of formula (1) as defined in any of the preceding claims wherein the metal is di- or tripositive and has a coordination number 6 or greater.
8. A metal complex according to Claim 8 wherein the metal is indium, copper, lead, bismuth, yttrium, terbium, gadolinium or scandium.
9. A yttrium complex of a compound of formula (1) as defined in Claims 1 to 7.
10. A compound according to any of the preceding claims wherein d is an integer 1.

-27-

11. A compound of formula (1a)



wherein


R , R^1 , R^2 and R^3 , which may be the same or different, is each a hydrogen atom or an alkyl, alkoxyalkyl, $-\text{CO}_2\text{H}$, $-\text{SO}_3\text{H}$, $-\text{PO}_3\text{H}_2$ or aryl group;

L is a covalent bond or a linker group;

Z is a hydrogen atom or a reactive functional group, with the proviso that when L is a covalent bond Z is a reactive functional group; and metal complexes and/or salts thereof.

12. A compound according to Claim 11 wherein R , R^1 , R^2 and R^3 is each a $-\text{CO}_2\text{H}$ group.

13. A conjugate compound which comprises a compound of formula (1):



wherein

m and n, which may be the same or different, is each zero or an integer 1, 2, or 3;

d is zero or an integer 1, 2 or 3;

q is zero or an integer from 1 to 6 inclusive;

R, R¹, R² and R³, which may be the same or different, is each a hydrogen atom or an alkyl, alkoxyalkyl, -CO₂H, -SO₃H, -PO₃H₂ or aryl group;


L is a covalent bond or a linker group;

Z is a hydrogen atom or a reactive functional group, with the proviso that when L is a covalent bond Z is a reactive functional group;

or a metal complex and/or salt thereof, coupled to a protein, peptide or carbohydrate.

-29-

14. A conjugate compound of formula (2)



wherein

m and n, which may be the same or different, is each zero or an integer 1, 2, or 3;

d is zero or an integer 1, 2 or 3;

q is zero or an integer from 1 to 6 inclusive;

R, R¹, R² and R³, which may be the same or different, is each a hydrogen atom or an alkyl, alkoxyalkyl, -CO₂H, -SO₃H, -PO₃H₂ or aryl group;

L is a covalent bond or linker group;

Z¹ is the residue of a reactive functional group


w is zero or an integer 1

z is an integer 1 or more

Ab is an antibody; and metal complexes and/or salts thereof.

15. A composition comprising a compound of formula (1) as defined in Claim 1 or a metal complex and/or salt thereof together with one or more pharmaceutically acceptable carriers.

16. A composition comprising a compound of formula (2) as defined in Claim 14 or a metal complex and/or salt thereof with one or more pharmaceutically acceptable carriers.
17. A process for the preparation of a compound of formula (1) as defined in Claim 1 or a metal complex thereof comprising reacting a compound of formula (3)




(3)

[where m, n, d, L and Z are as defined for the compound of formula (1)] or a metal complex thereof with a reagent $R^1(CH_2)_qD$ [where D is a displaceable group and R^1 and q are as defined for the compound of formula (1)].

18. A process for the preparation of a conjugate compound of formula (2) as defined in Claim 14 comprising reacting a compound of formula (1) as defined in Claim (1) with an antibody Ab.

INTERNATIONAL SEARCH REPORT

International Application No PCT/G888/00671

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁴ According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC ⁴ : C 07 D 257/02, C 07 D 401/12, A 61 K 39/44, A 61 K 49/00		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
IPC ⁴	C 07 D; A 61 K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹		
Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	American Chemical Society, ACS Symposium series, 1984, No. 241 (O A GANSOW et al.): "Generator- -Produced Bi-212. Chelated to Chemically Modified Monoclonal Antibody for Use in Radiotherapy" --	13-14, 18
Y	Analytical Biochemistry 148, (1985) p. 249-253, (M K MOI et al.): "Copper Chelates as Probes of Biological Systems: Stable Copper Complexes with a Macrocyclic Bifunctional Chelating Agent" --	1-18
Y,P	DE, A1, 36 25 417 (SCHERING AG) 11 February 1988 see the whole document --	1-18
Y,P	EP, A1, 0 255 471 (SCHERING AG) 3 February 1988 see the whole document --	1-18
./.		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report ¹⁴	
26th October 1988	22 NOV 1988	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	 P.C.G. VAN DER PUTTEN	

III. D DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y,P	WO, A1, 87/05030 (CELLTECH LIMITED) 27 August 1987 see the whole document --	1-18

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

GB 8800671
SA 23704

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 17/10/88. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE-A- 3625417	11-02-88	EP-A- 0255471 JP-A-63041468	03-02-88 22-02-88
EP-A- 0255471	03-02-88	DE-A- 3625417 JP-A-63041468	11-02-88 22-02-88
WO-A- 8705030	27-08-87	EP-A- 0238196	23-09-87

EPO FORM P001

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

